Skip to main content
Menu

Posts tagged with "Business and Markets"

  • Business and Markets

    Bristol-Myers Squibb and Celgene

    So our big biopharma news this morning is Bristol-Myers Squibb buying Celgene, for $74 billion. I don’t think anyone saw this particular combination coming, so congratulations to those involved for running a tight ship. It looks at first glance like Celgene shareholders are getting a pretty good deal out of the offer, and I would… Read More
  • Business and Markets

    Worse Than Useless

    Time for another look at AbbVie’s work on Rova-T (an antibody-drug conjugate targeting the tumor antigen DLL3), and for some hard thoughts about what drug development is really like. The last time I wrote about this program, things didn’t look good. Now they look even worse. A Phase III trial of the drug has been… Read More
  • Business and Markets

    Whatever Happened to Insourcing? The Case of AMRI/Lilly

    Albany Molecular (AMRI) has been a big name in contract research for many years now. They’ve had a lot of twists and turns in their history, including being taken private a couple of years ago after having taken on a good deal of debt by acquiring other companies in turn. But it sounds like they’re… Read More
  • Business and Markets

    Big Cuts at Bayer

    So the Bayer/Monsanto deal has gone through, and its sequel is exactly what you think it is: job cuts. About 10% of the company’s global work force is being let go. As some readers may know, I’ve already experienced the joys of losing a job as a result of a big Bayer move (in my… Read More
  • Business and Markets

    The Dark Side of a Wonderful Investment Story

    Biopharma investing has been a constantly erupting geyser of cash these last few years, and wherever there is that amount of money flying around, you will find people ready to help make it disappear. And you’ll find people who are willing to stretch the truth in any way that they find necessary to get in… Read More
  • Business and Markets

    Anarchist Drugs For All. Yeahboy.

    I’ve had numerous requests for my opinion about this article, so here it comes: it’s largely bullshit. It’s about “a volunteer network of anarchists and hackers developing DIY medical technologies”, and I can see why Vice.com is running the article, because that drugs/anarchists/hackers combo is absolute catnip to thei… Read More
  • Alzheimer's Disease

    Biogen and Eisai: Let the Alzheimer’s Arguing Commence

    Well, the tease is over: Biogen and Eisai have released data on their Alzheimer’s antibody, BAN2401. And the situation is messy, as many had feared. The top-line results are mostly positive, but there are several confounding factors that make them a matter of argument (see below). The companies were scheduled to go public with the… Read More
  • Business and Markets

    Welcome to Right to Try

    Update: Brainstorm has now abandoned their Right-to-Try approach. Who’s next? That didn’t take long. That didn’t take long at all. The federal “Right to Try” bill was just signed the other week, and we already have a company that’s willing – no, eager – to try it out. I will now cruelly caricature som… Read More
  • Business and Markets

    That Other Kind of Job

    This tweet by ChemJobber caught my eye over the weekend. He’s referencing an article in the New Yorker on “The Bullshit-Job Boom”, which is a review of this new book by David Graeber at the London School of Economics. Graeber’s thesis is that there is a higher and higher fraction of the labor market occupied… Read More
  • Alzheimer's Disease

    Bad Investments

    Here are some sequels to stories I’ve written about here, things that have had some new chapters added to them. First off, this 2015 post mentions the steep drop in shares of Clovis Biotechnology, brought on by a rather sudden revision in the announced clinical performance of their lead drug (the covalent kinase inhibitor rociletinib). Well… Read More
...234...